In addition, the trio, namely analogs (septide, Dpr3ghr, HM01, neurotensin2, and neurotensin4), agonists (septide, senktide, HM01, and PACAP (1–38)), and antagonists (NAT, L-733060, LY303870, and [D-Lys3]-GHRP6), of these NPs were as well employed in order to safeguard against nerve cell toxin-precipitated DArgic nerve cell devastation, as well as motor and nonmotor deficiencies, thereby furnishing a newfangled and propitious therapeutic perspective for the management of PD. This evidence concerns the gene ADCYAP1 and Parkinson disease.